Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/28—Insulins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
  • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
  • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/007—Preparations for dry skin

Definitions

• Transdermal administration of therapeutic agents has many advantages, including convenience and gastrointestinal tract metabolism avoidance. But in the absence of penetration enhancing agents, many therapeutic agents are not capable of penetrating the skin in therapeutically effective concentrations. As such, compositions that facilitate the penetration of therapeutic agents through the skin are needed.
• compositions that ameliorate dry skin and increase or maintain skin hydration are also needed.
• compositions comprising a first component, a second component, a C 2-10 alkyl alcohol, and an organic acid having 1 to 25 carbon atoms, wherein the first and second components are further defined herein. Methods of making and using these compositions are also described.
• the term “comprising” may include the embodiments “consisting of” and “consisting essentially of”
• the terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that require the presence of the named ingredients/steps and permit the presence of other ingredients/steps.
• compositions or processes as “consisting of” and “consisting essentially of” the enumerated ingredients/steps, which allows the presence of only the named ingredients/steps, along with any impurities that might result therefrom, and excludes other ingredients/steps.
• approximating language may be applied to modify any quantitative representation that may vary without resulting in a change in the basic function to which it is related. Accordingly, a value modified by a term or terms, such as “about” and “substantially,” may not be limited to the precise value specified, in some cases. In at least some instances, the approximating language may correspond to the precision of an instrument for measuring the value.
• the modifier “about” should also be considered as disclosing the range defined by the absolute values of the two endpoints. For example, the expression “from about 2 to about 4” also discloses the range “from 2 to 4.” The term “about” may refer to plus or minus 10% of the indicated number.
• “about 10%” may indicate a range of 9% to 11%, and “about 1” may mean from 0.9-1.1.
• Other meanings of “about” may be apparent from the context, such as rounding off, so, for example “about 1” may also mean from 0.5 to 1.4.
• alkyl refers to straight chain and branched chains having the indicated number of carbon atoms, usually from 1 to 20 carbon atoms, for example 1 to 8 carbon atoms, such as 1 to 6 or 1 to 7 carbon atoms.
• C 1-6 alkyl encompasses both straight and branched chain alkyl of from 1 to 6 carbon atoms.
• butyl is meant to include n-butyl, sec-butyl, isobutyl and t-butyl; “propyl” includes n-propyl and isopropyl.
• alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, and the like.
• alkenyl refers to an unsaturated branched or straight-chain alkyl group having at least one carbon-carbon double bond.
• the group may be in either the cis or trans configuration about the double bond(s).
• the group may also be an aromatic group, for example, a phenyl or phenylene moiety.
• Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl; butenyls such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl; phenylene, and the like.
• an alkenyl group has from 2 to 20 carbon atoms.
• alkynyl refers to an unsaturated branched or straight-chain alkyl group having at least one carbon-carbon triple bond derived by the removal of two molecules of hydrogen from adjacent carbon atoms of the parent alkyl.
• Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl; and the like.
• an alkynyl group has from 2 to 20 carbon atoms.
• compositions that moisturize the skin or that facilitate and/or enhance the transdermal permeation of therapeutic agents through the skin.
• “moisturize” refers to increasing hydration or preventing further hydration loss.
• the term “transdermal permeation” includes both percutaneous delivery and transmucosal delivery, that is, passage through skin or mucosal tissue and into the bloodstream.
• the term “enhancing” refers to increasing the rate at which a therapeutic agent penetrates the skin or mucosal tissue and enters the bloodstream.
• These compositions include a first component, a second component, an alcohol, an organic acid, and, optionally, water.
• Other compositions of the disclosure further comprise a therapeutic agent.
• the first component comprises
• R is C 1-20 alkyl, C 2-20 alkenyl; or C 2-20 alkynyl; and y is 1 to 25;
• n and n are each independently 1 to 25;
• the first component is a compound of formula I.
• R is C 1-20 alkyl, which can either be a straight chain or branched alkyl.
• Preferred compounds of formula I wherein R is C 1-20 alkyl include, for example, is cetomacrogol 1000; octadecan-1-ol, ethoxylated; polyoxyethylene(12)tridecyl ether; polyoxyethylene(10)tridecyl ether; fatty alcohol polyoxyethylene ether, polyoxyethylene branched nonylcyclohexyl ether (TRITON N-101), nonaethylene glycol monododecyl ether, 23- ⁇ [4-(2,4,4-trimethyl-2-pentanyl)cyclohexyl]oxy ⁇ -3,6,9,12,15,18,21-heptaoxatricosan-1-ol, and combinations thereof.
• Nonaethylene glycol monododecyl ether is particularly preferred.
• R is C 2-20 alkenyl, which can either be a straight chain or branched alkenyl.
• Preferred compounds of formula I wherein R is C 2-20 alkenyl include, for example, polyoxyl(10)oleyl ether, polyethylene glycol tert-octylphenyl ether (TRITON X-100), and combinations thereof.
• R is C 2-20 alkynyl, which can either be a straight chain or branch alkynyl.
• y is 1 to 25. In preferred embodiments, y is 5 to 15, preferably 8 to 10, with 9 being particularly preferred. In other embodiments, y is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
• the first component is a tetrafunctional block copolymer surfactant terminating in primary hydroxyl groups.
• tetrafunctional block copolymer surfactant terminating in primary hydroxyl groups.
• Such compounds are commercially available under the tradename TETRONIC and include ethylenediaminetetrakis(ethoxylate-Block-propoxylate).
• the first component is a sorbitan derivative, for example, polyoxyethylene sorbitan tetraoleate, 1,4-anhydro-6-O-palmitoyl-D-glucitol (sorbitan, monohexadecanoate), a polyethylene glycol sorbitan monolaurate (e.g., TWEEN 20, TWEEN 40, TWEEN 60, TWEEN 85), and combinations thereof.
• a sorbitan derivative for example, polyoxyethylene sorbitan tetraoleate, 1,4-anhydro-6-O-palmitoyl-D-glucitol (sorbitan, monohexadecanoate), a polyethylene glycol sorbitan monolaurate (e.g., TWEEN 20, TWEEN 40, TWEEN 60, TWEEN 85), and combinations thereof.
• the first component is a C 8-10 alkyl ammonium salt, for example, methyltrialkyl(C 8 -C 10 )ammonium chloride (ADOGEN 464).
• the first component is a compound of formula II.
• compositions of the disclosure can comprise from about 0.1 vol. % to about 40 vol. % of the first component. In preferred embodiments, the compositions comprise from about 1 vol. % to about 40 vol. % of the first component. In other embodiments, the compositions comprise from about 0.1 vol. % to about 5 vol. % of the first component.
• compositions can comprise about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or about 40 vol. % of the first component.
• compositions also include a second component that comprises
• each R 1 is independently H or C 1-3 alkyl
• R 2 and R 3 are independently C 1-7 alkyl or together with the atoms to which they are attached, form a lactam having 3 to 10 carbon atoms,
• the second component is compound of formula III.
• R 1 is H.
• R 1 is methyl, ethyl, propyl, or isopropyl, with methyl being particularly preferred.
• each of R 2 and R 3 is independently methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, hexyl, or heptyl.
• R 2 and R 3 together with the atoms to which they are attached, form a lactam having 3 to 10 carbon atoms.
• the lactam can include 3, 4, 5, 6, 7, 8, 9, or 10 carbons, which can be a part of the lactam ring or which can form exocyclic branching.
• preferred lactams include pyrrolidones such as 2-pyrrolidone, 1-methyl-2-pyrrolidone, 5-methyl-2-pyrrolidone, and 1-ethyl-2-pyrrolidone.
• the lactam is 1-methyl-2-pyrrolidinone or 2-pyrrolidone.
• the second component is a sulfoxide, for example, dimethyl sulfoxide.
• the second component is a urea, for example an imidazolidinone.
• compositions of the disclosure can comprise from about 0.01 vol. % to about 10 vol. % of the second component. In preferred embodiments, the compositions comprise from about 0.01 vol. % to about 5 vol. % of the second component. In other embodiments, the compositions comprise from about 0.01 vol. % to about 4 vol. % of the second component.
• the compositions can comprise about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or about 10 vol. % of the second component.
• the ratio, by volume, of the first component to the second component is about 10:1 to about 4:1.
• Alcohols for use in the compositions of the disclosure include C 2-10 alkyl alcohols having at least one —OH moiety or at least two —OH moieties.
• preferred alcohols include glycerol, propylene glycol, ethanol, isopropanol, 1-propanol, butanol, t-butanol, pentanol, 1-octanol, and combinations thereof, with ethanol being particularly preferred.
• compositions of the disclosure can comprise from about 0.1 vol. % to about 50 vol. % of the C 2-10 alkyl alcohol. In preferred embodiments, the compositions comprise from about 1 vol. % to about 50 vol. % of the C 2-10 alkyl alcohol. In other embodiments, the compositions comprise from about 0.1 vol. % to about 5 vol. % of the C 2-10 alkyl alcohol.
• compositions can comprise about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 48, 49, or about 50 vol. % of the C 2-10 alkyl alcohol.
• compositions of the disclosure also include an organic acid having 1 to 25 carbon atoms.
• organic acids for use in the disclose compositions include acetic acid, ascorbic acid, lactic acid, glycolic acid, propionic acid, and combinations thereof
• fatty acids include fatty acids.
• fatty acid has its ordinary meaning as would be understood by a person of ordinary skill in the art and includes a molecule having a carboxylic group and a hydrocarbon chain. Descriptions of the number of carbon atoms in a fatty acid herein refer to the number of carbon atoms in the hydrocarbon chain of the fatty acid, irrespective of whether the hydrocarbon chain is straight or branched.
• fatty acid includes saturated fatty acids, which do not contain any double or triple bonds in the hydrocarbon chain.
• Saturated fatty acids include, but are not limited to propionic acid (C3) (by way of example, C3 indicates propionic acid has 3 carbon atoms in its hydrocarbon chain; the number of carbon atoms in the hydrocarbon chain of other example fatty acids is denoted in analogous fashion herein), butyric acid (C4), valeric acid (C5), caproic acid (C6), enanthic acid (C7), caprylic acid (C8), pelargonic acid (C9), capric acid (C10), undecylic acid (C11), lauric acid (C12), tridecylic acid (C13), myristic acid (C14), pentadecylic acid (C15), palmitic acid (C16), margaric acid (C17), stearic acid (C18), isostearic acid (C18), nonadecylic acid (C3)
• C3
• fatty acid also includes monounsaturated fatty acids, which contain one double or triple bond in the hydrocarbon chain, and polyunsaturated fatty acids, which contain more than one double and/or triple bond in the hydrocarbon chain.
• Such acids include, but are not limited to the omega 3, omega 6, omega 9 fatty acids, other fatty acids such as myristoleic and palmitoleic acid and conjugated fatty acids.
• Examples of monounsaturated and polyunsaturated fatty acids include but are not limited to, (a) omega 3 fatty acids, such as hexadecatrienoic acid (C16:3); (by way of example, C16:3 indicates hexadecatrienoic acid has 16 carbon atoms in its hydrocarbon chain and 3 double bonds; the number of carbon atoms and double bonds in the hydrocarbon chain of other example unsaturated fatty acids is denoted in analogous fashion herein), alpha linolenic acid (C18:3) and eicosapentanoic acid (20:5), (b) omega 6 fatty acids, such as linoleic acid (18:2), docosadienoic acid (C22:2), arachidonic acid (C20:4) and tetracosatetraenoic acid (C24:5), (c) omega 9 fatty acids, such as oleic acid (C18:1), eicosenoic acid (C20:1) and
• fatty acid also includes branched fatty acids.
• branched fatty acids include, but are not limited to, monomethyl branched fatty acids, such as 14-methyl pentadecanoic acid, 6-methyl caprylic acid, 4-methyl-3-pentenoic acid, (pyroterebic acid), 2-methyl-2E-butenoic acid (tiglic acid), 2-methyl-2Z-butenoic acid (angelic acid), multimethyl branched acids, isoprenoid fatty acids (vittatalactone, all-trans-retinoic acid), branched methoxy fatty acids and hydroxy and other fatty acids such as 2-hydroxyoctanoic acid and 4-oxopentanoic acid.
• compositions of the disclosure can comprise from about 0.01 vol. % to about 15 vol. % of the organic acid. In some embodiment, the compositions comprise from about 1 vol % to about 15 vol % of the organic acid. In preferred embodiments, the compositions comprise from about 0.01 vol. % to about 5 vol. % of the organic acid. In other embodiments, the compositions comprise from about 0.01 vol. % to about 3 vol. % of the organic acid.
• compositions can comprise about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, or about 15 vol. % of the organic acid.
• compositions of the disclosure can be anhydrous.
• anhydrous refers to compositions comprising less than 1 vol. % of water, preferably less than 0.05 vol. % or less than 0.025 vol. % of water. Methods of determining water content are known in the art.
• compositions of the disclosure can include water.
• the compositions can comprise up to 99 vol. % of water.
• the compositions can comprise 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or 99 vol. % of water.
• the compositions can comprise 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 vol. % of water.
• compositions of the disclosure that include water can optionally contain one or more physiologically acceptable salts. While not being bound by any particular theory, it is believed that controlling the amount of salt that is present allows one to control the depth to which the present composition penetrate skin, with the concentration of salt having a generally inverse relationship to the penetration depth.
• Salts for use in the compositions include, but are not limited to, sodium chloride, potassium chloride, and mixtures thereof.
• a preferred form of sodium chloride is bacteriostatic sodium chloride solution.
• compositions of the disclosure can also include a therapeutic agent.
• therapeutic agent refers to a compound that, upon administration to a patient in a therapeutically effective amount, provides a therapeutic benefit to the patient.
• a therapeutic agent may be referred to herein as a drug or biologic.
• therapeutic agent is not limited to drugs or biologics, or to materials that have received regulatory approval.
• such therapeutic agents include, but are not limited to, hormones such as estrogens, progestins, and androgens for both male and female health, adrenocortical steroids and their synthetic analogs for inflammation and/or various manifestations of adrenal insufficiency or pituitary hormone excess, antinausea/antiemetic drugs, tricyclic antidepressants, migraine and other pain drugs including NSAIDs and narcotics, hypnotics, some beta blockers, alpha blockers, neuromuscular blocking agents, diuretics, antimalarial drugs, dermatologicals, antimetabolites, peptides such as leuprolide, goserelin or histrelin.
• hormones such as estrogens, progestins, and androgens for both male and female health
• adrenocortical steroids and their synthetic analogs for inflammation and/or various manifestations of adrenal insufficiency or pituitary hormone excess antinausea/antiemetic drugs
• the therapeutic agent may be, but is not limited to, an agent to treat Alzheimer's, an anabolic agent, an analgesic agent, an anesthetic agent, an antacid, an anti-asthmatic agent, an anticholesterolemic agent, an anti-lipid agent, an anti-coagulant, an anti-convulsant, an anti-diarrheal, an antiemetic, an anti-inflammatory agent, an antifungal agent, an anti-manic agent, an anti-migraine, an anti-nauseant, a CNS anti-depressant, an antineoplastic agent, an anti-obesity agent, an anti-Parkinson's agent, an anti-pyretic agent, an anti-spasmodic agent, an anti-thrombotic agent, an anti-uricemic agent, an anti-anginal agent, an antihistamine, an anti-tussive, an appetite suppressant, a biological, a cerebral dilator, a central nervous system agent, a coronary
• Therapeutics also include benzoyl peroxide, salicylic acid, iodine, and oregano oil.
• therapeutic agents suitable for use in compositions of the invention include ropinirole, pramipexole, sumatriptan, zolmitriptan, rizatriptan, almotriptan, eletriptan, naratriptan, frovatriptan, zolpidem, zaleplon, eszopiclone, ramelteon, doxepin, ketoprofen, ketorolac, piroxicam, meloxicam, diclofenac, mifepristone, ulipristal, sildenafil, vardenafil, tadalafil, alprostadil, letrozole, anastrozole, oxycodone, hydrocodone, buprenorphine, fentanyl, sufentanyl, alfentanyl, morphine, naloxone, naltrexone, leuprolide, goserelin, histrelin, pyridoxine,
• compositions of the invention include estrogens, which can be useful as contraceptives and/or hormone therapies for menopause and other endocrine conditions.
• Suitable estrogens not mentioned elsewhere in this specification include ethinyl estradiol and estradiol-17beta.
• progesterones and progestins are useful as contraceptives, hormone therapies, or both, for menopause and other endocrine conditions.
• Suitable progesterones and progestins not mentioned elsewhere in this specification include: Progesterone, Norgestimate, Norelgestromin (also called 17-deacetyl norgestimate), Norgestrel, Levo-norgestrel, Cyproterone Acetate, Gestodene, Desogestrel, Dienogest, Drosperinone, Norethindrone, and Norethindrone acetate.
• compositions of the invention include anti-infectives.
• anti-infectives include Fenticonazole (base, nitrate or both) and Fluconazole.
• Additional compounds suitable for use in compositions of the invention include nutritional supplements and vitamins.
• Suitable nutritional supplements and vitamins not mentioned elsewhere in this specification include Calcium Carbonate, Cholecalciferol (a metabolite of Vitamin D), Folic Acid, Folate, and Metafolin.
• compositions of the invention include compounds useful for treating central nervous system (CNS) disorders.
• Suitable compounds useful for treating central nervous system (CNS) disorders not mentioned elsewhere in this specification include Methylphenidate (e.g., for ADHD), Paroxetine (base, mesylate salt, or both), Valproic Acid, Lithium carbonate, Fentanyl, Lidocaine, and Rivastigmine.
• a composition of the invention includes a therapeutic agent that is a serotonin receptor antagonist.
• the serotonin receptor antagonist comprises a 5-HT 3 receptor antagonist.
• the serotonin receptor antagonist is selected from ondansetron, dolasetron, granisetron, tropisetron, palonosetron, or salts thereof
• compositions of the invention may be designed to be administered to the skin or mucosal tissue of a patient in need of treatment.
• Compositions of the invention may be formulated as gels, transdermal patches, lotions, creams, sprays, mists, emulsions, or dispersions.
• Appropriate excipients for formulating a gel, transdermal patch, lotion, cream, spray, or mist are readily apparent to a person of skill in the art and include, but are not limited to, stabilizers, emulsifiers, thickeners, antimicrobials, humectants, propellants, spreading agents, polymers, and adhesives, such as pressure sensitive adhesives.
• excipients that may be used to form a transdermal gel include, but are not limited to, alcohols, glycols, glycerin, butylated hydroxytoluene (BHT), and water.
• compositions comprising administering any of the described compositions to the skin of a mammal for a time and under conditions effective to achieve passage of at least a portion of the composition through the skin.
• Skin permeation can be measured using techniques known in the art.
• compositions of the disclosure can be used to administer a therapeutic agent to a mammal.
• these methods comprise applying any of the described compositions to the skin of a mammal for a time sufficient to achieve permeation of at least a portion of the therapeutic agent through the skin.
• Therapeutic agent skin permeation can be measured using techniques known in the art.
• compositions of the disclosure can be used in methods of moisturizing the skin.
• these methods can comprising identifying on a mammal an area of skin having an undesirably low level of moisture and applying any of the described compositions to the skin.
• the level of moisture is increased or does not decrease.
• compositions described herein can be applied to any convenient skin surface.
• Skin surfaces of interest include, but are not limited to: arms, leg, torso, head, neck, etc.
• the surface area that is covered by the transdermal formulation following application is generally sufficient to provide for the desired amount of agent administration, and in certain embodiments ranges from about 1 cm 2 to about 200 cm 2 .
• compositions described herein can be applied a single time or a plurality of times over a given time period, e.g., the course of the disease condition being treated, where the dosing schedule when a plurality of patches are administered over a given time period may be daily, weekly, biweekly, monthly, etc.
• compositions of the disclosure will, in some embodiments, include, in addition to the above-discussed components, one or more additional components.
• Additional components include, but are not limited to, a transdermal absorption enhancer, a preservative (e.g., paraben), an antioxidant, a stabilizing agent, a filling agent that contains a hydrophilic polymer; a cross-linking agents; and a plasticizing agent.
• Nonaethylene glycol monododecyl ether (3 mL, 5.14 vol %), 1-methyl-2-pyrrolidinone (0.3 mL, 0.515 vol. %), ethanol (4 mL, 6.86 vol. %), oleic acid (1 mL, 1.72 vol. %), and water (50 mL, 85.8 vol. %) are combined to form an admixture.
• the resulting composition is applied to an area of the skin that is dry or in need of moisture in order to alleviate symptoms of dry skin.
• Nonaethylene glycol monododecyl ether (3 mL), 1-methyl-2-pyrrolidinone (0.3 mL), ethanol (4 mL), oleic acid (1 mL), and water (50 mL) are combined to form an admixture.
• An effective amount of a therapeutic agent is combined with the admixture to form a transdermal composition.
• the transdermal composition is applied to the skin of a patient in an amount and for a time sufficient for the therapeutic agent to permeate through the skin and into the patient's bloodstream to achieve a therapeutic effect.
• Nonaethylene glycol monododecyl ether (3 mL), 1-methyl-2-pyrrolidinone (0.3 mL), ethanol (4 mL), and linoleic acid (1 mL) are combined to form an admixture.
• An effective amount of a therapeutic agent is combined with the admixture to form a transdermal composition.
• the transdermal composition of Example 3 is applied to the skin of a patient in an amount and for a time sufficient for the therapeutic agent to permeate through the skin and into the patient's bloodstream to achieve a therapeutic effect.
• Example 3 The composition of Example 3 (1 mL) is mixed with 99 mL of water.
• the resulting aqueous composition can be applied to a sensitive tissue, for example a mucous membrane, for a time sufficient for the therapeutic agent to permeate through the sensitive tissue and into the patient's bloodstream to achieve a therapeutic effect.
• a sensitive tissue for example a mucous membrane
• Example 3 The composition of Example 3 (1 mL) is mixed with water 49 mL of water.
• the resulting aqueous composition can be applied to normal skin for a time sufficient for the therapeutic agent to permeate through the skin and into the patient's bloodstream to achieve a therapeutic effect.
• Nonaethylene glycol monododecyl ether (3 mL), 1-methyl-2-pyrrolidinone (0.3 mL), ethanol (4 mL), and linoleic acid (1 mL) are combined.
• Insulin (3 mL, 100 units/mL, LANTUS SOLOSTAR, Sanofi) is then added to form an admixture.
• the admixture (1 mL) is then combined with 24 mL of water.
• the resulting aqueous composition can be applied to skin or tissue for a time sufficient for the insulin to permeate through the skin or tissue and into the patient's bloodstream to achieve a therapeutic effect.
• Nonaethylene glycol monododecyl ether (3 mL), 1-methyl-2-pyrrolidinone (0.3 mL), ethanol (4 mL), and linoleic acid (1 mL) are combined.
• Insulin (3 mL, 100 units/mL, LANTUS SOLOSTAR, Sanofi) is then added to form an admixture.
• the admixture (1 mL) is then combined with 32.3 mL of water.
• the resulting aqueous composition can be applied to skin or tissue for a time sufficient for the insulin to permeate through the skin or tissue and into the patient's bloodstream to achieve a therapeutic effect.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Birds (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Emergency Medicine (AREA)
• Dermatology (AREA)
• Diabetes (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Endocrinology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Toxicology (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Cosmetics (AREA)

Priority Applications (3)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=55221489

Family Applications (3)

Family Applications After (2)

Country Status (14)

Families Citing this family (11)

Citations (3)

Family Cites Families (18)

• 2015
  • 2015-12-23 KR KR1020177020147A patent/KR20170117390A/ko unknown
  • 2015-12-23 WO PCT/US2015/000302 patent/WO2016105530A1/en active Application Filing
  • 2015-12-23 BR BR112017013329A patent/BR112017013329A2/pt not_active IP Right Cessation
  • 2015-12-23 ES ES15828407T patent/ES2953955T3/es active Active
  • 2015-12-23 EP EP15828407.5A patent/EP3237013B1/en active Active
  • 2015-12-23 EA EA201791454A patent/EA035087B1/ru not_active IP Right Cessation
  • 2015-12-23 MX MX2017008423A patent/MX2017008423A/es unknown
  • 2015-12-23 CA CA2968046A patent/CA2968046A1/en not_active Abandoned
  • 2015-12-23 CN CN201580069944.7A patent/CN107405298A/zh active Pending
  • 2015-12-23 JP JP2017528802A patent/JP6836991B2/ja active Active
  • 2015-12-23 AU AU2015371253A patent/AU2015371253B2/en active Active
• 2016
  • 2016-03-11 US US15/067,677 patent/US20160193339A1/en not_active Abandoned
• 2017
  • 2017-05-01 IL IL252062A patent/IL252062A0/en unknown
  • 2017-05-05 PH PH12017500836A patent/PH12017500836A1/en unknown
• 2019
  • 2019-03-05 US US16/292,811 patent/US10786574B2/en active Active
• 2020
  • 2020-09-28 US US17/034,406 patent/US20210008214A1/en not_active Abandoned
  • 2020-10-28 JP JP2020180706A patent/JP2021020955A/ja active Pending

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events